No Data
No Data
AstraZeneca Cut to Sell From Hold by Deutsche Bank
AstraZeneca Target Cut to 10500p From 11000p by Deutsche Bank
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Kepler Capital Sticks to Their Hold Rating for AstraZeneca (AZN)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
AstraZeneca Analyst Ratings
No Data
No Data